Balanced news tone
News Sentiment
EOLS sentiment intelligence
Evolus Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
54
Balanced news tone
57 relevant articles
Price is moving more forcefully than the current news tone suggests.
77/100 classification confidence.
directly relevant articles
high-authority source matches
-4.2% over one week, -1.8% over four weeks, trend active, and below fair value.
Analysts Conflicted on These Healthcare Names: Irhythm Technologies (IRTC), Penumbra (PEN) and Evolus (EOLS)
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
77/100 classification
One-week reaction
-4.2%
Price reacting lower
Trend fit
Trend active
-1.8% over four weeks
Fair value
-33.8%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
17
Neutral
33
Negative
7
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
The Globe and Mail
Direct company coverage
Analysts Conflicted on These Healthcare Names: Irhythm Technologies (IRTC), Penumbra (PEN) and Evolus (EOLS)
This article highlights recent analyst ratings for several healthcare companies. Irhythm Technologies (IRTC) received a "Strong Buy" consensus with a significant upside, while Penumbra (PEN) garnered a "Hold" consensus. Evolus (EOLS) also received a "Strong Buy" consensus rating
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 15 Jul 2026 12:12
- Source
- The Globe and Mail
Stock Titan
Direct company coverage
Evolus issues stock-based hiring incentives to 38 new employees
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 20:05
- Source
- Stock Titan
Yahoo! Finance Canada
Direct company coverage
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. announced the grant of 115,000 restricted stock units (RSUs) to 38 newly hired non-executive employees between April and July 2026. These inducement awards were approved by the compensation committee under Evolus' 2023 Inducement Incentive Plan, as material inducemen
- Tone
- Positive 62/100
- Event
- Market update
- Published
- 10 Jul 2026 16:05
- Source
- Yahoo! Finance Canada
TMX Newsfile
Direct company coverage
Evolus Class Action Reminder
Faruqi & Faruqi, LLP is reminding investors who suffered losses exceeding $100,000 in Evolus (NASDAQ: EOLS) stock or options between February 1, 2019, and July 6, 2020, to contact them. The firm is investigating potential claims that Evolus made misleading statements regarding it
- Tone
- Negative 30/100
- Event
- Market update
- Published
- 10 Jul 2026 08:39
- Source
- TMX Newsfile
TradingView
Direct company coverage
ETFs Investing in Evolus, Inc. Stocks
This article lists various ETFs that invest in Evolus, Inc. (EVL) stocks, providing details such as market value, weight, issuer, management style, expense ratio, and AUM. The funds primarily focus on small-cap, total market, micro-cap, and healthcare sectors, offering investors
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 08:40
- Source
- TradingView
Moomoo
Direct company coverage
Evolus Partners With IBSA to Develop, Commercialize Profhilo in US
Evolus has partnered with IBSA to develop and commercialize Profhilo, an injectable aesthetic treatment, in the United States. This collaboration aims to bring a new bio-remodeling product to the US market, expanding Evolus's portfolio beyond neuromodulators and adding an immedia
- Tone
- Positive 72/100
- Event
- Market update
- Published
- 09 Jul 2026 03:39
- Source
- Moomoo
The Dermatology Digest
Direct company coverage
Evolus, IBSA Partner to Develop and Commercialize Skin Quality Filler in the US
Evolus has entered into an exclusive licensing and distribution agreement with IBSA to develop and commercialize Profhilo, a hyaluronic acid-based injectable for skin quality improvement, in the United States. This partnership expands Evolus's presence in the aesthetic market, ta
- Tone
- Positive 71/100
- Event
- Deals and strategy
- Published
- 08 Jul 2026 15:39
- Source
- The Dermatology Digest
Investing.com
Direct company coverage
Evolus signs licensing deal for Profhilo skin injectable in US
Evolus Inc. has signed an exclusive licensing and distribution agreement with IBSA to commercialize Profhilo, a hyaluronic acid skin injectable, in the United States. This agreement allows Evolus to expand its aesthetic product portfolio, complementing its existing neurotoxin and
- Tone
- Positive 66/100
- Event
- Deals and strategy
- Published
- 08 Jul 2026 13:39
- Source
- Investing.com
Investing.com Canada
Direct company coverage
Evolus signs licensing deal for Profhilo skin injectable in US By Investing.com
Evolus Inc. has signed an exclusive licensing and distribution agreement with Swiss pharmaceutical company IBSA to bring Profhilo, a hyaluronic acid skin injectable, to the United States. This strategic move expands Evolus's aesthetic product portfolio, which already includes Jeu
- Tone
- Positive 74/100
- Event
- Deals and strategy
- Published
- 08 Jul 2026 13:18
- Source
- Investing.com Canada
TradingView
Direct company coverage
Evolus Secures Exclusive U.S. Profhilo License From IBSA; No Upfronts, 15-Year Term
Evolus has secured an exclusive 15-year U.S. license, supply, and distribution agreement with IBSA for Profhilo, an injectable hyaluronic acid product for skin quality. Evolus will manage the U.S. development, clinical work, and regulatory approval, with no upfront or milestone p
- Tone
- Positive 71/100
- Event
- Regulatory and legal
- Published
- 08 Jul 2026 13:13
- Source
- TradingView
Stock Titan
Direct company coverage
Evolus adds Profhilo, a skin-quality injectable sold in 70+ countries
Evolus, Inc. announced an exclusive licensing and distribution agreement with IBSA to bring Profhilo®, a leading skin-quality injectable, to the United States. This partnership expands Evolus's injectable portfolio into the rapidly growing skin quality segment, complementing its
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 08 Jul 2026 13:12
- Source
- Stock Titan
Yahoo! Finance Canada
Direct company coverage
Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality
Evolus, Inc. has partnered with IBSA to exclusively license and commercialize Profhilo® in the United States, expanding Evolus's injectable portfolio into the skin quality segment. Profhilo® is a market-leading injectable in Europe designed to improve skin quality, hydration, ela
- Tone
- Positive 71/100
- Event
- Deals and strategy
- Published
- 08 Jul 2026 09:00
- Source
- Yahoo! Finance Canada
Stock Traders Daily
Direct company coverage
(EOLS) and the Role of Price-Sensitive Allocations
This article provides an analysis of Evolus Inc. (NASDAQ: EOLS) based on AI-generated signals for July 7, 2026. It highlights a near-term weak sentiment but mid-term strength within a broader long-term weak bias, noting compelling upside potential due to the absence of resistance
- Tone
- Negative 36/100
- Event
- Market update
- Published
- 07 Jul 2026 03:16
- Source
- Stock Traders Daily
Finviz
Direct company coverage
EOLS - Evolus Inc Options
This page provides a detailed financial overview of Evolus Inc (EOLS) options, including its latest stock price, financial metrics, and performance indicators. It covers market capitalization, income, sales, various ratios, insider ownership, institutional ownership, profitabilit
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 19:11
- Source
- Finviz
TradingView
Direct company coverage
Enterprise value to EBITDA forward of Evolus, Inc. Common Stock – NASDAQ:EOLS
This page from TradingView provides financial information for Evolus, Inc. Common Stock (NASDAQ: EOLS), specifically focusing on its enterprise value to EBITDA forward metric. It highlights the company's financial overview within the health technology and pharmaceutical sectors.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jun 2026 13:09
- Source
- TradingView
MSN
Direct company coverage
Evolus (EOLS) price target decreased by 11.11% to 14.96
The price target for Evolus (EOLS) has been decreased by 11.11%, bringing it down to $14.96. Further details are not available in the provided content.
- Tone
- Negative 31/100
- Event
- Analyst action
- Published
- 28 Jun 2026 11:09
- Source
- MSN
TradingView
Direct company coverage
Evolus, Inc. Actuals & Estimates (NASDAQ:EOLS)
This article provides actuals and estimates for Evolus, Inc. (NASDAQ:EOLS), including financial data, analyst forecasts, and various stock performance metrics. It covers the company's current stock price, historical highs and lows, volatility, market capitalization, and earnings
- Tone
- Positive 61/100
- Event
- Earnings
- Published
- 26 Jun 2026 09:11
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of Evolus, Inc. Common Stock – NASDAQ:EOLS
This article provides access to the "Price to sales forward" financial metric for Evolus, Inc. Common Stock (NASDAQ: EOLS) on the TradingView platform. It highlights that this data is part of the financials section for EOLS, indicating its availability for users analyzing the com
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 09:09
- Source
- TradingView
TradingView
Direct company coverage
EOLS Forecast — Price Target — Prediction for 2027
The article provides a forecast and price target for Evolus, Inc. (EOLS) stock for 2027, based on analyst ratings and the company's financial performance. It includes current stock price information, historical highs and lows, market capitalization, volatility, and details on ear
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 25 Jun 2026 16:09
- Source
- TradingView
TradingKey
Direct company coverage
Evolus Inc (EOLS) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Evolus Inc (EOLS), detailing its price momentum score of 9.32 within the Pharmaceuticals industry. It identifies current support at $6.35 and resistance at $7.55, suggesting suitability for range-bound swing trading. The analysis incl
- Tone
- Positive 77/100
- Event
- Market update
- Published
- 24 Jun 2026 09:09
- Source
- TradingKey
Kavout
Direct company coverage
Is Evolus (EOLS) Finally Turning the Corner on Profitability
Evolus (EOLS) reported strong Q1 2026 results, beating revenue expectations with $73.1 million, driven by demand for Jeuveau and growth in Evolisse. The company achieved its second consecutive quarter of positive Adjusted EBITDA, signaling progress toward full-year profitability
- Tone
- Positive 63/100
- Event
- Earnings
- Published
- 21 Jun 2026 00:40
- Source
- Kavout
TradingKey
Direct company coverage
Evolus Inc (EOLS) Financial Health: Profitability & Balance Sheet Analysis
Evolus Inc (EOLS) has a financial score of 8.00, placing it 84th out of 157 in the Pharmaceuticals industry, indicating a weak financial status but high operating efficiency. The company reported a quarterly revenue of $73.14M, marking a 6.74% year-over-year increase, and net pro
- Tone
- Positive 71/100
- Event
- Earnings
- Published
- 18 Jun 2026 19:09
- Source
- TradingKey
TradingKey
Direct company coverage
Evolus Inc (EOLS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article provides a revenue breakdown for Evolus Inc (EOLS). However, it states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The page displays current stock information for EOLS, including
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 11:40
- Source
- TradingKey
TradingKey
Direct company coverage
Evolus Inc (EOLS) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Evolus Inc (EOLS), identifying major shareholders by proportion and type, as well as institutional holdings over various quarters. It highlights key individual and institutional investors and their recent activities, alongside rel
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 11:40
- Source
- TradingKey
TradingKey
Direct company coverage
Evolus Inc (EOLS) Earnings Forecast: Future EPS & Revenue Growth Estimates
Evolus Inc (EOLS) has an earnings forecast score of 8.57, ranking 28th in the Pharmaceuticals industry. Analysts have a consensus "Buy" rating for EOLS, with an average price target of $19.50, suggesting a significant upside of over 121% from its current price of $6.63. The expec
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 06:40
- Source
- TradingKey
GuruFocus
Direct company coverage
EOLS Reiterated by BTIG -- Price Target Maintained at $13.00
BTIG has reiterated a Buy rating for Evolus (EOLS), maintaining a price target of $13.00. Despite strong growth potential (GF Score Growth 10/10), the company faces challenges in Financial Strength and Profitability (both 3/10). The stock is considered 51.0% undervalued by GuruFo
- Tone
- Positive 65/100
- Event
- Analyst action
- Published
- 17 Jun 2026 11:10
- Source
- GuruFocus
TradingKey
Direct company coverage
Evolus Inc (EOLS) Institutional Confidence
Evolus Inc (EOLS) has an institutional shareholding score of 7.00, ranking 51st in the Pharmaceuticals industry. The institutional shareholding proportion is 75.98%, a decrease of 14.84% quarter-over-quarter. James Simons is the largest institutional shareholder, with other signi
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 05:40
- Source
- TradingKey
Stock Titan
Direct company coverage
[EFFECT] Evolus, Inc. SEC Filing
This article provides details on an SEC filing (Form EFFECT) by Evolus, Inc. The filing indicates an effectiveness date of June 12, 2026, for Form S-3. It also includes company information, recent news, and other SEC filings for Evolus.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 10:39
- Source
- Stock Titan
Stock Traders Daily
Direct company coverage
Understanding the Setup: (EOLS) and Scalable Risk
This article provides an analysis of Evolus Inc. (NASDAQ: EOLS) using AI models to suggest trading strategies. It highlights mixed sentiment, potential upside due to lack of resistance, and offers specific position trading, momentum breakout, and risk hedging strategies. The anal
- Tone
- Positive 64/100
- Event
- Market update
- Published
- 15 Jun 2026 00:56
- Source
- Stock Traders Daily
Investing.com
Direct company coverage
Evolus shareholders re-elect directors and approve executive compensation
Evolus Inc. shareholders re-elected Brady Stewart and Vikram Malik as Class II directors for three-year terms and ratified Ernst & Young LLP as the independent public accounting firm. Shareholders also approved the compensation of the company’s named executive officers in an advi
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 14 Jun 2026 19:09
- Source
- Investing.com